Business
Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee™ Oxygen and Glucose Monitoring Launches
EU commercialization expected in early 2026; U.S. entry and expanded indications to follow as digital-health pioneer advances tissue-integrated biosensor platform BERKELEY, Calif, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, outlines its path to revenue generation led by Lumee tissue oxygen m
About this update from Profusa, Inc.
[{"type":"image","alt":"Profusa, Inc.","displaySize":"","headline":null,"caption":"Profusa, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":71,"url":"https://media.zenfs.com/en/globenewswire.com/8f79cba194228307ca23a2955a9ec150"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C0XqXJTHmuw3t23BmCcCpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEyODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8f79cba194228307ca23a2955a9ec150","width":200,"height":71}},"lazy":false},{"type":"text","content":"EU commercialization expected in early 2026; U.S. entry and expanded indications to follow as digital-health pioneer advances tissue-integrated biosensor platform","length":162,"tagName":"p"},{"type":"text","content":"BERKELEY, Calif, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, outlines its path to revenue generation led by Lumee tissue oxygen monitoring, with commercialization in the European Union (EU) expected in the beginning of 2Q 2026.","length":435,"tagName":"p"},{"type":"text","content":"Following recently-announced manufacturing capabilities, intended distributor partnerships, and commercial and clinical collaboration wins, Profusa estimates it now has approximately 35% of the European population covered through its intended distribution channels. Combined with expanding coverage in Europe and planned geographic reach into the United States markets, as well as potential additional indications on its Lumee technology platform – such as continuous glucose monitoring – Profusa anticipates $200 to $250 million in potential revenue by 2030.","length":565,"tagName":"p"},{"type":"text","content":"“We believe Profusa is bringing to market a first-of-its-kind, disruptive biochemistry monitoring platform designed for use both in the clinic and at home,” said Ben Hwang, Ph.D., Profusa’s Chairman and CEO. “Backed by more than a decade of development and over $100 million in investment, our Lumee™ technology enables continuous, real-time measurement of tissue oxygen directly within the body—offering a less invasive, more convenient experience for patients while reducing costs for healthcare systems and insurers throu...